KCG Holdings Inc. bought a new stake in Fortress Biotech, Inc. (NASDAQ:FBIO) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 50,831 shares of the biopharmaceutical company’s stock, valued at approximately $188,000. KCG Holdings Inc. owned about 0.10% of Fortress Biotech as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Geode Capital Management LLC boosted its position in shares of Fortress Biotech by 3.2% in the first quarter. Geode Capital Management LLC now owns 288,566 shares of the biopharmaceutical company’s stock valued at $1,067,000 after buying an additional 8,958 shares in the last quarter. ClariVest Asset Management LLC boosted its position in shares of Fortress Biotech by 1.0% in the first quarter. ClariVest Asset Management LLC now owns 161,519 shares of the biopharmaceutical company’s stock valued at $598,000 after buying an additional 1,600 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Fortress Biotech by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 110,061 shares of the biopharmaceutical company’s stock valued at $408,000 after buying an additional 5,170 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors.

Shares of Fortress Biotech, Inc. (NASDAQ FBIO) remained flat at $4.14 on Friday. The company had a trading volume of 171,633 shares. The stock has a 50 day moving average price of $4.65 and a 200 day moving average price of $3.69. The firm’s market capitalization is $208.37 million. Fortress Biotech, Inc. has a one year low of $1.88 and a one year high of $5.07.

Fortress Biotech (NASDAQ:FBIO) last posted its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.06. Fortress Biotech had a negative net margin of 269.14% and a negative return on equity of 63.99%. The company had revenue of $2.78 million for the quarter, compared to analyst estimates of $47.04 million. Equities research analysts predict that Fortress Biotech, Inc. will post ($1.20) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/06/kcg-holdings-inc-purchases-new-stake-in-fortress-biotech-inc-nasdaqfbio.html.

Several brokerages have recently commented on FBIO. Zacks Investment Research cut shares of Fortress Biotech from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. HC Wainwright set a $11.00 target price on shares of Fortress Biotech and gave the stock a “buy” rating in a report on Tuesday, July 11th. Rodman & Renshaw began coverage on shares of Fortress Biotech in a report on Tuesday, July 11th. They set a “buy” rating and a $11.00 target price on the stock. FBR & Co reaffirmed a “buy” rating on shares of Fortress Biotech in a report on Tuesday, July 4th. Finally, ValuEngine raised shares of Fortress Biotech from a “sell” rating to a “hold” rating in a report on Wednesday, June 7th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $9.67.

Fortress Biotech Company Profile

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

Want to see what other hedge funds are holding FBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fortress Biotech, Inc. (NASDAQ:FBIO).

Institutional Ownership by Quarter for Fortress Biotech (NASDAQ:FBIO)

Receive News & Ratings for Fortress Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.